Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 27,778 | 2,830 | 169 | 741 | 965 |
| Gross Profit | 27,778 | 2,830 | 169 | 741 | 965 |
| Operating Expenses | 29,668 | 29,759 | 21,983 | 29,102 | 19,532 |
| Operating Income | -1,890 | -26,929 | -21,814 | -28,361 | -18,567 |
| Other Income | 3,197 | 4,206 | 1,963 | -3,120 | 2,889 |
| Pre-tax Income | 1,307 | -22,723 | -19,851 | -31,481 | -15,678 |
| Income Tax | 2,811 | 317 | 30 | 56 | 185 |
| Net Income Continuous | -1,504 | -23,040 | -19,881 | -31,537 | -15,863 |
| Net Income | $-1,504 | $-23,040 | $-19,881 | $-31,537 | $-15,863 |
| EPS Basic Total Ops | -0.14 | -2.21 | -3.00 | -3.04 | -1.53 |
| EPS Basic Continuous Ops | -0.14 | -2.21 | -3.00 | -3.04 | -1.53 |
| EPS Diluted Total Ops | -0.14 | -2.21 | 4.23 | -3.04 | -1.53 |
| EPS Diluted Continuous Ops | -0.14 | -2.21 | -2.82 | -3.04 | -1.53 |
| EPS Diluted Before Non-Recurring Items | N/A | -2.21 | -1.91 | -3.04 | -1.53 |
| EBITDA(a) | $-1,707 | $-27,002 | $-23,384 | $-27,468 | $-19,205 |